Robert Reiter

Current

Founder at EMTx Therapeutics
Founder and Chief Medical Officer at ImaginAb
Professor of Urology, Member Molecular Biology Institute, Director of Genitourinary Oncology at UCLA, Jonsson Comprehensive Cancer Center

see less...

Past

Urologic Oncology Fellow at National Cancer Institute

Education

University of California, Los Angeles - The Anderson School of Management
Stanford University School of Medicine
Yale University

see less...

Connections

32 connections

Industry

Biotechnology

Websites

My Company

Robert Reiter’s Summary

Professor of Urology specializing in urologic oncology, in particular practice of robotic prostatectomy. Dr. Reiter's laboratory cloned the Prostate Stem Cell Antigen and developed antibodies against it which have now entered clinical trials in prostate and pancreatic cancer.

Dr. Reiter was a Founder of Agensys, which was acquired by Astellas Pharmaceuticals in 2007 for almost 500 million dollars. He recently founded ImaginAb Corp, a biotechnology concern focused on the development of engineered antibodies for cancer diagnosis and drug development, and EMTx Therapeutics, which identifies and develops drugs targeting epithelial to mesenchymal transition in cancer.

Robert Reiter’s Experience

Founder

EMTx Therapeutics

(Biotechnology industry)

September 2008 — Present (11 months)

EMTx Therapeutics is a biotechnology company that discovers therapeutic and diagnostic targets of epithelial to mesenchymal transition and therapeutics towards these targets. We are actively seeking to partner our lead compound with a major biotechnology or pharmaceutical company.
Founder and Chief Medical Officer

ImaginAb

(Privately Held; Biotechnology industry)

September 2007 — Present (1 year 11 months)

ImaginAb is a diagnostic imaging company focused on the development of radiolabeled engineered antibodies for PET and SPECT imaging of cancers and other diseases. ImaginAb provides tailored molecules to the Biotechnology and Pharmaceutical industries for companion imaging of drugs in preclinical and clinical development. ImaginAb also develops engineered antibodies against proprietary cancer targets for diagnostic imaging.
Professor of Urology, Member Molecular Biology Institute, Director of Genitourinary Oncology

UCLA, Jonsson Comprehensive Cancer Center

(Educational Institution; Research industry)

September 1996 — Present (12 years 11 months)

Private practice specializing in urologic oncology, notably prostate cancer. The practice specializes in robotic prostatectomy, radical retropubic prostatectomy, brachytherapy for localized prostate cancer.

He is Director of the Prostate Cancer Treatment and Research Center at UCLA and is Principal Investigator of UCLA's Prostate Cancer SPORE from the NCI.

He also runs a basic and translational research lab focused on identification of novel targets and development of new drugs for prostate and other cancers.
Urologic Oncology Fellow

National Cancer Institute

(Government Agency; Medical Practice industry)

July 1991 — June 1993 (2 years)

Robert Reiter’s Education

University of California, Los Angeles - The Anderson School of Management

MBA , Business , 2005 — 2007
Stanford University School of Medicine

MD , Medicine , 1984 — 1988
Yale University

1979 — 1983